array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2748)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(66) "Regeneron loses bid to block Amgen's Eylea biosimilar launch in US"
["snippet_en"]=>
string(178) "Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said."
["url"]=>
string(139) "https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-launch-us-eylea-biosimilar-after-ruling-regeneron-patent-case-2024-10-22/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7e51f5f7-6c09-44a2-a8eb-8c20ed0d1ed8"
["source"]=>
string(11) "reuters.com"
["publication_date"]=>
string(10) "2024-10-22"
["categories"]=>
array(3) {
[0]=>
string(5) "Legal"
[1]=>
string(14) "Product Launch"
[2]=>
string(8) "Verdicts"
}
}
[1]=>
array(7) {
["title_en"]=>
string(97) "Regeneron Pharmaceuticals Stock: Court Defeat Impacts Outlook - Downgrade! (First Group Research)"
["snippet_en"]=>
string(114) "Regeneron Pharmaceuticals Stock: Court Defeat Impacts Outlook - Downgrade! (Erste Group Research) | aktiencheck.de"
["url"]=>
string(136) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Aktie_Gerichtsniederlage_belastet_Aussichten_Herabstufung-17606302"
["image_url"]=>
NULL
["source"]=>
string(14) "aktiencheck.de"
["publication_date"]=>
string(10) "2024-10-02"
["categories"]=>
array(7) {
[0]=>
string(12) "Stock Market"
[1]=>
string(5) "Legal"
[2]=>
string(17) "Business Disputes"
[3]=>
string(24) "Stock Research & Ratings"
[4]=>
string(18) "General Investment"
[5]=>
string(8) "Verdicts"
[6]=>
string(17) "Commodity Pricing"
}
}
[2]=>
array(7) {
["title_en"]=>
string(70) "Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (Fed. Cir. 2024)"
["snippet_en"]=>
string(151) "Ever since the Supreme Court's decision in Dickinson v. Zurko, federal courts (including the Federal Circuit) are compelled under the Administrative..."
["url"]=>
string(73) "https://www.jdsupra.com/legalnews/novartis-pharma-ag-v-regeneron-7195005/"
["image_url"]=>
NULL
["source"]=>
string(11) "jdsupra.com"
["publication_date"]=>
string(10) "2024-09-27"
["categories"]=>
array(2) {
[0]=>
string(5) "Legal"
[1]=>
string(8) "Verdicts"
}
}
[3]=>
array(7) {
["title_en"]=>
string(111) "Federal judge rules against Regeneron's attempt to halt Amgen from launching Eylea biosimilar"
["snippet_en"]=>
string(301) "Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in court from imminent competition, the US District Court for the Northern District of West Virginia"
["url"]=>
string(76) "https://endpts.com/regeneron-hits-setback-in-eylea-patent-battle-with-amgen/"
["image_url"]=>
NULL
["source"]=>
string(10) "endpts.com"
["publication_date"]=>
string(10) "2024-09-25"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(5) "Legal"
[2]=>
string(10) "Litigation"
[3]=>
string(21) "Competitive Behaviour"
[4]=>
string(8) "Verdicts"
}
}
[4]=>
array(7) {
["title_en"]=>
string(63) "Court denies Regeneron bid to halt copy of blockbuster eye drug"
["snippet_en"]=>
string(63) "Court denies Regeneron bid to halt copy of blockbuster eye drug"
["url"]=>
string(109) "https://www.lifesciencesipreview.com/americas/court-denies-regeneron-bid-to-halt-copy-of-blockbuster-eye-drug"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ccbf2d2b-2e2b-4bf5-9f98-acc272b42e42"
["source"]=>
string(24) "lifesciencesipreview.com"
["publication_date"]=>
string(10) "2024-09-25"
["categories"]=>
array(2) {
[0]=>
string(5) "Legal"
[1]=>
string(8) "Verdicts"
}
}
[5]=>
array(7) {
["title_en"]=>
string(62) "Regeneron Faces Setback After Court Ruling on Eylea Biosimilar"
["snippet_en"]=>
string(62) "Regeneron Faces Setback After Court Ruling on Eylea Biosimilar"
["url"]=>
string(108) "https://kalkinemedia.com/us/stocks/healthcare/regeneron-faces-setback-after-court-ruling-on-eylea-biosimilar"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3aac68df-7972-41df-bd93-ef0a3833780d"
["source"]=>
string(16) "kalkinemedia.com"
["publication_date"]=>
string(10) "2024-09-25"
["categories"]=>
array(2) {
[0]=>
string(5) "Legal"
[1]=>
string(8) "Verdicts"
}
}
[6]=>
array(7) {
["title_en"]=>
string(38) "Legal Lens on the Unified Patent Court"
["snippet_en"]=>
string(190) "The Unified Patent Court (UPC) is revolutionizing the way patents are enforced in Europe, and McDermott’s intellectual property team is here to help you navigate this dynamic landscape...."
["url"]=>
string(81) "https://www.jdsupra.com/legalnews/legal-lens-on-the-unified-patent-court-9286045/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/bf0f869d-23c7-46f1-80e7-1401254eded4"
["source"]=>
string(11) "jdsupra.com"
["publication_date"]=>
string(10) "2024-08-29"
["categories"]=>
array(4) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(21) "Competitive Behaviour"
[2]=>
string(5) "Legal"
[3]=>
string(8) "Verdicts"
}
}
[7]=>
array(7) {
["title_en"]=>
string(109) "The Supreme Court’s Narrowing of Mail and Wire Fraud May Affect RICO Litigation in the Health Care Industry"
["snippet_en"]=>
string(152) "The Supreme Court's narrowing of mail and wire fraud laws may impact RICO litigation in the healthcare industry, altering legal strategies and outcomes."
["url"]=>
string(105) "https://www.healthcarebusinesstoday.com/supreme-court-narrows-mail-wire-fraud-rico-litigation-healthcare/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fce8a85c-499b-49ae-85d0-fc59676caf54"
["source"]=>
string(27) "healthcarebusinesstoday.com"
["publication_date"]=>
string(10) "2024-07-12"
["categories"]=>
array(4) {
[0]=>
string(10) "Litigation"
[1]=>
string(5) "Legal"
[2]=>
string(8) "Verdicts"
[3]=>
string(5) "Fraud"
}
}
[8]=>
array(7) {
["title_en"]=>
string(74) "Dupixent gets closer to EU approval as the FDA delays its decision on COPD"
["snippet_en"]=>
string(127) "The CHMP has given a positive recommendation to Dupixent for COPD while the FDA has delayed its verdict from June to September."
["url"]=>
string(122) "https://www.pharmaceutical-technology.com/news/dupixent-gets-closer-to-eu-approval-as-the-fda-delays-its-decision-on-copd/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/aac0f631-aa04-4656-80ef-b1a38e94f8ed"
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2024-05-31"
["categories"]=>
array(1) {
[0]=>
string(8) "Verdicts"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(263)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(201)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(196)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(129)
}
[4]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(116)
}
[5]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(116)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(93)
}
[7]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(79)
}
[8]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(67)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(66)
}
[10]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(61)
}
[11]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(59)
}
[12]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(57)
}
[13]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(56)
}
[14]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(53)
}
[15]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(43)
}
[16]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(40)
}
[17]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(38)
}
[18]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(37)
}
[19]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(37)
}
[20]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(37)
}
[21]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(35)
}
[22]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[23]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(32)
}
[24]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(31)
}
[25]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(28)
}
[26]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(28)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(25)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(21) "Intellectual Property"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Website
https://www.regeneron.com
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Articles
2024-10-22 (reuters.com)
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
Read more
2024-10-02 (aktiencheck.de)
Regeneron Pharmaceuticals Stock: Court Defeat Impacts Outlook - Downgrade! (Erste Group Research) | aktiencheck.de
Read more
2024-09-27 (jdsupra.com)
Ever since the Supreme Court's decision in Dickinson v. Zurko, federal courts (including the Federal Circuit) are compelled under the Administrative...
Read more
2024-09-25 (endpts.com)
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in court from imminent competition, the US District Court for the Northern District of West Virginia
Read more
2024-09-25 (lifesciencesipreview.com)
Court denies Regeneron bid to halt copy of blockbuster eye drug
Read more
2024-09-25 (kalkinemedia.com)
Regeneron Faces Setback After Court Ruling on Eylea Biosimilar
Read more
2024-08-29 (jdsupra.com)
The Unified Patent Court (UPC) is revolutionizing the way patents are enforced in Europe, and McDermott’s intellectual property team is here to help you navigate this dynamic landscape....
Read more
2024-07-12 (healthcarebusinesstoday.com)
The Supreme Court's narrowing of mail and wire fraud laws may impact RICO litigation in the healthcare industry, altering legal strategies and outcomes.
Read more
2024-05-31 (pharmaceutical-technology.com)
The CHMP has given a positive recommendation to Dupixent for COPD while the FDA has delayed its verdict from June to September.
Read more
